Virulence and biofilms as promising targets in developing antipathogenic drugs against candidiasis

Mohd Sajjad Ahmad Khan1, Fatimah Alshehrei2, Saleh Bakheet Al-Ghamdi3

  • 1Department of Basic Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.

Future Science OA
|February 7, 2020
PubMed

Insights

Drug resistance in Candida albicans necessitates new treatments. Targeting virulence factors like enzymes, morphogenesis, and biofilms offers a promising strategy for novel antifungal drug development.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Candida albicans is a primary cause of candidiasis, leading to significant mortality and morbidity.
  • Existing antifungal drugs face challenges due to resistance, toxicity, and reduced efficacy.

Purpose of the Study:

  • To review recent advancements in understanding Candida albicans pathogenicity.
  • To explore novel drug targets for combating candidiasis.

Main Methods:

  • Literature review focusing on virulence factors and their regulation.
  • Analysis of molecular and metabolic pathways involved in pathogenicity.

Main Results:

  • Virulence factors such as hydrolytic enzymes, morphogenesis, and biofilm formation are crucial for C. albicans infection.
  • Understanding the regulation of these factors provides insights for therapeutic intervention.

Conclusions:

  • Targeting virulence factor production is a viable alternative strategy for developing new anti-infectives.
  • Further research into the molecular regulation of C. albicans pathogenicity can guide novel drug design.